Navigation Links
CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
Date:3/1/2012

BRUSSELS, March 1, 2012 /PRNewswire/ -- CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat congenital bleeding disorders, immune deficiencies, hereditary angioedema and inherited respiratory disease, is a subsidiary of CSL Limited (ASX:CSL).

(Logo:  http://photos.prnewswire.com/prnh/20100914/PH63692LOGO )

One of the primary criteria for the award is a demonstrated commitment to providing access to therapies for people with rare diseases. The award was presented yesterday at the first EURORDIS Gala Dinner in the Hotel Le Plaza. "Solidarity," the theme of 2012 Rare Disease Day, focuses on the importance and the need for collaboration in the field of rare diseases.

"CSL Behring is honored and delighted to receive a 2012 EURORDIS Award," said Senior Vice President of Public Affairs Dennis Jackman. "This award is a reflection of our commitment to providing safe and effective therapies to improve the lives of patients with rare and serious medical conditions.  CSL Behring's commitment is further demonstrated in the company's growing investment in research and development, which has added to an extensive rare disease product portfolio, and in advanced manufacturing facilities and patient support."

CSL Behring received the National Organization for Rare Disorders 2011 Corporate Award for new treatments for rare diseases brought to market in the U.S.

About EURORDIS

EURORDIS is a non-governmental, patient-driven alliance of patient organisations and individuals active in the field of rare diseases, dedicated to improving the quality of life of all people living with rare diseases in Europe.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com or view CSL Limited's Corporate Responsibility Report.

Contact:
Chris Florentz
Manager, Corporate Communications
610-878-4316
Christopher.Florentz@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
2. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
3. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
4. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
5. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
6. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
7. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
8. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
9. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
10. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
11. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... India 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India ... registered the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with ...
(Date:5/2/2016)...  While nearly three-quarters of Americans (71%) are aware ... health, only about half report taking any steps to ... a new survey announced today by Hologic (Nasdaq: ... Osteoporosis Month, Hologic is raising awareness of this major ... Americans. Osteoporosis is a disease that causes ...
(Date:5/2/2016)... The global  ultrasound device ... by 2024, according to a new report published ... the sonography market include expanding applications of the ... periodic ultrasound screenings of the breast for breast ... ) High Intensity Focused Ultrasound (HIFU) ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due ... Diego. Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered ... since 2009. , “I’m excited for our eighth summer here in San Diego,” ...
(Date:5/4/2016)... ... ... Washington Wellness Center today announced its tenth anniversary of providing a complete approach to ... idea to provide a holistic approach to wellness has now become a growing trend ... Chiropractic Physician , the wellness center offers a complete range of services such ...
(Date:5/4/2016)... Watsonville, California (PRWEB) , ... May 04, 2016 ... ... powerful formulation of foundational nutrients that supports cellular and metabolic health. This synergistic ... and 400 mg free-form curcumin, along with 150 mg of reduced glutathione and ...
(Date:5/4/2016)... ... 04, 2016 , ... The preeminent surgical aftercare facility Pearl Recovery Retreat was ... surgery. In March 2016, the 61-year-old model and reality TV star was diagnosed with ... the milk ducts, according to an interview with the Daily Mail Online . ...
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , There ... UTIs, have plagued people since the beginning of recorded medical history, and in ... every year. It's not just a matter of inconvenience; bladder infections cost us billions ...
Breaking Medicine News(10 mins):